All In Biotech

Drug Trial Radar · NCT03719313

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)

Last checked: Nov 19, 2026Latest source record: Apr 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 407 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

407

Actual

Start

Dec 1, 2018

Primary completion

Oct 6, 2022

Study completion Mar 24, 2023

Sponsor

Lead sponsor
Eiger BioPharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Two LNF-containing regimens will be evaluated in the D-LIVR Phase 3 study: (1) LNF/RTV/PEG IFN-alfa-2a and (2) LNF/RTV. Each of these arms will have efficacy endpoints that measure clinical benefit with regard to viral suppression and alanine aminotransferase (ALT) normalization. For each LNF-containing regimen, a composite endpoint of EOT (48 weeks) virologic response and ALT normalization will be used. Virologic response will be defined as a 2 log10 IU/mL reduction from baseline.

Conditions

  • Hepatitis Delta Virus

Interventions

  • LonafarnibDrug

    Lonafarnib (LNF) 50 mg BID

  • RitonavirDrug

    Ritonavir (RTV) 100 mg BID

  • PEG IFN-alfa-2aDrug

    PEG IFN alfa-2a 180 mcg QW

  • Placebo LonafarnibDrug

    Placebo

  • Placebo RitonavirDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the composite virologic and biochemical response rate at end-of-treatment (EOT) in patients who receive LNF 50 mg/RTV 100 mg BID vs patients who receive placebo.Time frame: 48 weeks
  2. To compare the composite virologic and biochemical response rate at EOT in patients who receive LNF 50 mg/RTV 100 mg BID with PEG IFN-alfa-2a 180 mcg QW vs patients who receive placebo.Time frame: 48 weeks

Locations

116 sites in 22 countries. Site status is shown where the registry gives one.

  • UCSF Fresno

    Fresno, California

  • Ruane Clinical Research Group Inc.

    Los Angeles, California

  • Asia Pacific Liver Center

    Los Angeles, California

  • Stanford University

    Palo Alto, California

  • University of California Davis Health System

    Sacramento, California

  • Kaiser Permanente Medical Center Sacramento

    Sacramento, California

  • Yale University Medical Center

    New Haven, Connecticut

  • University of Miami Schiff Center for Liver Disease

    Miami, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa

  • National Institutes of Health

    Bethesda, Maryland

  • Henry Ford Health System

    Detroit, Michigan

  • Mt. Sinai Hospital

    New York, New York

  • NYU Langone Medical Center

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Central Sooner Research

    Norman, Oklahoma

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Baylor St. Luke's Medical Center

    Houston, Texas

  • ZNA Stuivenberg

    Antwerp, Belgium

  • C.H.U. Brugmann

    Brussels, Belgium

  • Cliniques Universitaires de Bruxelles Hopital Erasme

    Brussels, Belgium

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • CHU Sart Tilman

    Liège, Belgium

  • Acibadem City Clinic Tokuda Hospital Ead

    Sofia, Bulgaria

  • UMHAT "Alexandrovska" EAD

    Sofia, Bulgaria

  • UMHAT "Sv. Ivan Rilski", EAD

    Sofia, Bulgaria

  • Medical Center "Nov Rehabilitatsionen Tsentar", EOOD

    Stara Zagora, Bulgaria

  • University of Calgary

    Calgary, Alberta, Canada

  • University Health Network

    Toronto, Ontario, Canada

  • Toronto Liver Centre

    Toronto, Ontario, Canada

  • McGill University Health Centre/Glen Site / Royal Victoria Hospital

    Montreal, Quebec, Canada

  • CHU Nice - Hôpital de l'Archet 2

    Nice, Alpes Maritimes, France

  • CHU Strasbourg - Hôpital Hautepierre

    Strasbourg, Bas Rhin, France

  • CHU Bordeaux - Hôpital Haut-Lévêque

    Pessac, Gironde, France

  • Hôpital Beaujon

    Clichy, Hauts De Seine, France

  • CHU de Grenoble - Hôpital Nord

    La Tronche, Isere, France

  • Centre Hospitalier de la Croix Rousse

    Lyon, Rhone, France

  • Hôpital Jean Verdier

    Bondy, Seine Saint Denis, France

  • Hôpital Paul Brousse

    Villejuif, Val De Marne, France

  • Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH

    Berlin, Germany

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.